IGF1R — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL94862	1.00	20/20
SCHEMBL95142	1.00	20/20
SCHEMBL94964	0.79	20/20
SCHEMBL57094	0.62	17/20
SCHEMBL57586	0.52	17/20
SCHEMBL56620	0.69	16/20
SCHEMBL56235	0.54	14/20
SCHEMBL57809	0.74	12/20
SCHEMBL56519	0.63	9/20
SCHEMBL63471	0.60	9/20
SCHEMBL56922	0.49	9/20
SCHEMBL107170	0.90	7/20
SCHEMBL69580	0.79	7/20
SCHEMBL68664	0.64	7/20
SCHEMBL57394	0.56	7/20
SCHEMBL20952	0.53	7/20
SCHEMBL68207	0.76	6/20
SCHEMBL70343	0.76	6/20
SCHEMBL83311	0.45	6/20
Dopamine (SCHEMBL49885)	0.57	5/20

Clinical trials — most relevant to IGF1R by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer	PHASE4	WITHDRAWN
Metformin in Longevity Study (MILES).	PHASE4	COMPLETED
Cinnamomum Cassia Effect on IGF1 and Metabolic Control in Patients With DM2 Without Glycemic Control Metformin Treated	PHASE3	COMPLETED
Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis	PHASE3	COMPLETED
MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer	PHASE2	COMPLETED
Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer	PHASE2	COMPLETED
Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung	PHASE2	COMPLETED
Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma	PHASE2	COMPLETED
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck	PHASE2	COMPLETED
Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)	PHASE2	COMPLETED
A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)	PHASE2	COMPLETED
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors	PHASE1	WITHDRAWN
Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate	PHASE1	COMPLETED
A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects	PHASE1	COMPLETED
Serum IGF-1 and IGF-1Ec in Malignancy Assessment	nan	ACTIVE_NOT_RECRUITING
IRS Proteins and Trastuzumab Resistance	nan	COMPLETED
IGF and Other Neurotrophic Factors in Patients With Dementia	nan	COMPLETED
In Vivo IGF-1R Molecular Imaging Using [68Ga]- Labelling Anti-IGF-1R Affibody Molecule	nan	UNKNOWN
AR, IGF-IR, IR and Peripheral Artery Disease	nan	UNKNOWN
Osteoprosis in Type 2 Diabetic Patients- a Cohort Study	nan	UNKNOWN
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.	nan	COMPLETED
BRCA Main Home Nutritional Intervention-random Study	nan	UNKNOWN
Blood and Tissue Study of Patients in NIH Protocol 08-C-0800	nan	COMPLETED
Genetic Study of Insulin-Like Growth Factor-I Receptor Mutations in Patients With Intrauterine Growth Retardation	nan	UNKNOWN
The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans	nan	UNKNOWN
Cell Signaling, Reinnervation and Metabolism in Kennedy Disease and Amyotrophic Lateral Sclerosis (ALS)	nan	UNKNOWN
Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle	nan	UNKNOWN
Epidemiology of Insulin Growth Factor (IGF) and Cardiovascular Events	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a IGF1R binder may also engage these)

Protein	Name	Similarity
Q60751	—	1.000	Q60751 →
P24062	—	1.000	P24062 →
O73798	—	1.000	O73798 →
Q93105	—	0.999	Q93105 →
INSR	Insulin receptor	0.997	landscape →
Q9PVZ4	—	0.997	Q9PVZ4 →
P15127	—	0.996	P15127 →
O02466	—	0.995	O02466 →
P15208	—	0.993	P15208 →
EPHA6	Ephrin type-A receptor 6	0.990	landscape →
Q02858	—	0.990	Q02858 →
P54757	—	0.989	P54757 →
P26619	—	0.989	P26619 →
PTPRM	Receptor-type tyrosine-protein phosphatase mu	0.988	landscape →
O18016	—	0.988	O18016 →
Q75ZY9	—	0.988	Q75ZY9 →
Q25410	—	0.988	Q25410 →
Q07E01	—	0.988	Q07E01 →
Q5GIT4	—	0.988	Q5GIT4 →
Q2QLA9	—	0.988	Q2QLA9 →
Q09YK0	—	0.988	Q09YK0 →
Q9I8N6	—	0.988	Q9I8N6 →
Q769I5	—	0.988	Q769I5 →
A1X150	—	0.988	A1X150 →
Q62413	—	0.987	Q62413 →
Q8JFR5	—	0.987	Q8JFR5 →
P14617	—	0.987	P14617 →
Q108U6	—	0.987	Q108U6 →
P43481	—	0.987	P43481 →
Q07DZ1	—	0.987	Q07DZ1 →